ERIC ROHREN was named chair of radiology at Baylor College of Medicine. His appointment is effective Oct. 1. Rohren currently serves as a professor in the Departments of Nuclear Medicine and Diagnostic Radiology at MD Anderson Cancer Center, and is chief of the Section of Positron Emission Tomography. Rohren has been on the MD Anderson... […]
FDA approved Kyprolis (carfilzomib) in combination with lenalidomide and dexamethasone for the treatment of patients with relapsed multiple myeloma who have received one to three prior lines of therapy. Kyprolis is sponsored by Onyx Pharmaceuticals Inc., an Amgen subsidiary.
FDA approved Odomzo (sonidegib) capsules for the treatment of patients with locally advanced basal cell carcinoma that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy. Odomzo is marketed by Novartis Pharmaceuticals Corp.
CHARLES ROBERTS was named executive vice president and director of the St. Jude Comprehensive Cancer Center, effective Sept. 1.
NCI and FDA are recruiting three medical oncologists who would divide their time between clinical and regulatory duties—half at the FDA Office of Oncology and Hematology Products, and half at the NCI Center for Cancer Research.
IriSys LLC was awarded a five-year contract worth up to $3 million by the NCI Developmental Therapeutic Program of the Division of Cancer Treatment and Diagnosis for the pharmaceutical development and production of new therapeutic agents for use in clinical trials supported by NCI. Under this agreement, IriSys will be supplying NCI with oral, topical... […]
FDA granted priority review to MM-398 in patients with metastatic adenocarcinoma of the pancreas who have been previously treated with gemcitabine-based therapy.
FDA granted Fast Track designation to immuno-oncology products Toca 511 and Toca FC, developed by Tocagen Inc., for the treatment of recurrent high grade glioma, including glioblastoma and anaplastic astrocytoma. A study in this indication is planned for later this year, according to Tocagen.
FDA granted an Orphan Drug Designation to Cleave Biosciences' lead drug candidate, CB-5083, for treatment of multiple myeloma.CB-5083 is a first-in-class, oral inhibitor of p97, an enzyme that controls various aspects of protein homeostasis.
The European Commission approved Imbruvica capsules (ibrutinib) for adult patients with Waldenstrom's macroglobulinemia who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy.
